We have some exciting news to share! The Motley Fool UK has now become an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. We’ll be introducing a new name and brand over the coming weeks — we're very excited to share it with you and embark on this new chapter together!

Saga shares are surging. Here’s what I’d do next

Recent vaccine news helped Saga shares in November. After the share price doubled, have I missed the boat?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Saga (LSE: SAGA) shares are on an upswing. The company’s share price increased by 34% on Wednesday. And as I write on Thursday, it’s up another 5%. The strong share price reaction follows news that Pfizer’s coronavirus vaccine appears to be 94% effective for the over-65s. News that the Moderna and AstraZeneca vaccines work well for older people has helped too.

Last week, Pfizer had announced its vaccine to tackle Covid-19 was 90% effective. US pharmaceutical giant Moderna followed with an announcement that its vaccine solution appears to be 95% effective. And AstraZeneca’s news has come today.

Saga shares benefited from these vaccine announcements with the share price doubling since the start of November.

The shares have risen an incredible 50% since I recently wrote about and considered buying them. It was one of two cheap shares in the travel sector that I looked at buying in anticipation of an economic recovery next year. 

Saga targets the over-50s in two main business areas, insurance and travel. News of high vaccine effectiveness for the over-65s could help it significantly.

Is it too late to buy Saga shares?

I’m kicking myself now because I didn’t act earlier, but am I too late to buy? No, I don’t think it’s too late to buy for the long term. These cheap and unloved shares could still get a further significant re-rating if Covid-19 is brought under control next year. I reckon there’s significant pent-up demand from UK holidaymakers who missed out this year.

The target market for Saga also tend to be wealthier and cash-rich. Once travelling is safer, I think confidence will return to the battered travel sector, and cruises will return to being as popular as they once were.

But I also think Saga shares could be more volatile in the short term. 

Hurdles could provide a buying opportunity

While recent vaccine news has created optimism and improved the chances of an economic recovery next year, there are still hurdles to overcome.

We currently don’t know which vaccine(s) will be most suitable. Also, it could take many months to distribute and vaccinate enough of the population. There could be a difficult winter period coming with an extension to lockdowns. Vaccine delays could cause Saga shares to fall in the short term.

However, over the coming year, I think Saga could be a good turnaround story. It has had 15 years of under-investment in its brand. But it has outlined its turnaround plan, which could be the shot in the arm that it needs to reinvigorate the weakened brand.

Saga is a less risky share compared to a pureplay cruise provider due to it operating in both insurance and travel, I feel. The insurance part of the business provides stability and cash flow. The travel side of the business provides significant upside if Covid-19 is brought under control and an economic recovery follows.

Overall, any weakness in Saga shares over the coming weeks and months could be a great buying opportunity, in my opinion.  

Harshil Patel has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Two female adult friends walking through the city streets at Christmas. They are talking and smiling as they do some Christmas shopping.
Investing Articles

How much is £7,620 saved in a Cash ISA a decade ago worth today?

Cash ISA savers have received an average of 4% over the last decade, but Harvey Jones says the average Stocks…

Read more »

Close-up as a woman counts out modern British banknotes.
Investing Articles

702 shares in this FTSE 100 stalwart earn a £100 a month second income

Unilever shares come with an unusually high dividend yield. Should investors looking for a second income grab the opportunity with…

Read more »

UK coloured flags waving above large crowd on a stadium sport match.
Investing Articles

This surging FTSE 100 share just hit £201! Will it ever split its stock? 

This high-quality FTSE 100 stock is up by a staggering 4,050% in the past 10 years. Why hasn't it split…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

Just over £13 after its Q1 results, here’s why HSBC shares still look a bargain-basement buy for me anywhere below £20.68

HSBC shares have surged, but fresh results hint the market may still be missing a major value opportunity that long…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

GSK’s share price is down 18% despite another set of strong results! Time for me to buy more for under £19 while I can?

GSK’s share price has fallen far below what its earnings strength implies, creating a huge price-valuation gap long-term investors won't…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

A 6.7% forecast yield and 53% under ‘fair value’! 1 FTSE income share to buy today?

This FTSE income share looks deeply undervalued despite its high payouts and cash flows, creating a rare opportunity that yield…

Read more »

Close-up of British bank notes
Investing Articles

Here’s how I’m targeting £11,363 in yearly second income from £20,000 in Aberdeen shares!

Aberdeen shares have delivered consistently high yields for years, which, when compounded, could turn a £20k investment into very high…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

Here’s how investors could make £1,654 a month in retirement from just £20,000 in Standard Life shares

Passive income seekers might overlook Standard Life shares, whose dividend machine is accelerating fast. The long-term payout maths is startling.

Read more »